Kevan Herold, MD

Professor of Immunobiology and of Medicine (Endocrinology); Deputy Director for Translational Science, YCCI; Director, Yale Diabetes Center

Clinical Interests

  • Diabetes Mellitus, Type 1

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Child
Referrals: From patients or physicians

Patient Care Organizations

Internal Medicine: Diabetes Research Center | Endocrinology: Diabetes Center

Yale Medical Group

Clinical Trials

Conditions Study Title
Anti-CD3 (Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at risk for Type 1 Diabetes Mellitus
Type 1 Diabetes TrialNet - Natural History Study of the Development of Type 1 Diabetes
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients with Type I Diabetes
CTLA-4 Ig (Abatacept) FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS
Collection of Peripheral Blood Cells for the Study of Type 1 Diabetes, Type 2 Diabetes and Other Autoimmune Diseases
Yale Center for Clinical Investigation (YCCI) Specimen and Data Repository
LONG TERM INVESTIGATIVE FOLLOW-UP IN TRIALNET (LIFT) (Protocol TN-16)
Mobilization of human stem cells with G-CSF for creation of personalized humanized mice
ITN027AI Follow Up Study
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OFMULTIPLE ASCENDING DOSES OF PF-06342674 (RN168) IN ADULTS WITH TYPE 1 DIABETES
Antithymocyte Globulin (ATG) and pegylated granulocyte colony stimulating factor (GCSF) in New Onset Type 1 Diabetes (Protocol TN-19)

Edit this profile

Contact Info

Kevan Herold, MD
Patient Care Locations
Yale EndocrinologyDana Clinic Building
789 Howard Avenue, Fl 2nd

New Haven, CT 06519
Yale-New Haven Hospital
20 York Street

New Haven, CT 06510
Mailing Address
300 George St
New Haven, CT 06511

Herold Lab